Anthus Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 12-12-2024
- Paid Up Capital ₹ 9.23 M
as on 12-12-2024
- Company Age 25 Year, 27 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 4.01 Cr
as on 12-12-2024
- Revenue 20.27%
(FY 2022)
- Profit -28.71%
(FY 2022)
- Ebitda 117.50%
(FY 2022)
- Net Worth 16.07%
(FY 2022)
- Total Assets 4.54%
(FY 2022)
About Anthus Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 9.23 M.
The company currently has active open charges totaling ₹4.01 Cr.
Kuttichira Mohanan, Vembra Ramdas, Hari Nair, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24231TN1999PTC043816
- Company No.
043816
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Dec 1999
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Anthus Pharmaceuticals Private Limited offer?
Anthus Pharmaceuticals Private Limited offers a wide range of products and services, including Diabetes Medicine.
Who are the key members and board of directors at Anthus Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kuttichira Mohanan  | Managing Director | 23-Dec-1999 | Current |
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Hari Nair | Director | 23-Dec-1999 | Current |
| Vembra Ramdas | Director | 23-Dec-1999 | Current |
| Bajy Joseph | Director | 23-Dec-1999 | Current |
| Joseph Cherian | Director | 23-Dec-1999 | Current |
Financial Performance of Anthus Pharmaceuticals.
Anthus Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 20.27% increase. The company also saw a substantial fall in profitability, with a 28.71% decrease in profit. The company's net worth Soared by an impressive increase of 16.07%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Anthus Pharmaceuticals?
In 2021, Anthus Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 24 Feb 2023 | ₹7.74 M | Open |
Hdfc Bank Limited Creation Date: 12 Aug 2022 | ₹7.38 M | Open |
Hdfc Bank Limited Creation Date: 07 Feb 2014 | ₹1.00 Cr | Open |
How Many Employees Work at Anthus Pharmaceuticals?
Unlock and access historical data on people associated with Anthus Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Anthus Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Anthus Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
